(19)

(11)

EP 3 654 971 A1

(12)

(43) Date of publication: 27.05.2020 Bulletin 2020/22 (21) Application number: 18835211.6 (22) Date of filing: 18.07.2018

(51) International Patent Classification (IPC):  A61K 31/415(2006.01) A61K 31/437(2006.01) C07D 231/10(2006.01) A61K 31/4353(2006.01) C07D 231/00(2006.01) C07D 231/14(2006.01) (86) International application number: PCT/US2018/042707 (87) International publication number: WO 2019/018536 (24.01.2019 Gazette 2019/04)

(84) Designated Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR Designated Extension States: BA ME Designated Validation States: KH MA MD TN (30) Priority: 18.07.2017 US 201762533894 P (71) Applicant: Vyripharm Enterprises, LLC Houston, TX 77021 (US)	(72) Inventors: BRYANT, Jerry, L., Jr. Houston, TX 77021 (US) YANG, David, J. Houston, TX 77021 (US) RAUVOLFOVA, Jana Houston, TX 77021 (US) STRONG, Tori Houston, TX 77021 (US) (74) Representative: Thurston, Joanna  Withers & Rogers LLP 4 More London Riverside London SE1 2AU London SE1 2AU (GB)